The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Corey Cutler

Department of Medical Oncology

Division of Hematological Malignancies

Dana-Farber Cancer Institute

450 Brookline Avenue

USA

[email]@*.harvard.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medical Oncology, Division of Hematological Malignancies, Dana-Farber Cancer Institute, 450 Brookline Avenue, USA. 2011
  • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. 2010
  • Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. 2004 - 2010
  • Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, USA. 2001 - 2006
  • Harvard Medical School, Boston, USA. 2005

References

  1. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Cutler, C., Kim, H.T., Sun, L., Sese, D., Glotzbecker, B., Armand, P., Koreth, J., Ho, V., Alyea, E., Ballen, K., Ritz, J., Soiffer, R.J., Milford, E., Antin, J.H. Blood (2011) [Pubmed]
  2. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Cutler, C., Kim, H.T., Ayanian, S., Bradwin, G., Revta, C., Aldridge, J., Ho, V., Alyea, E., Koreth, J., Armand, P., Soiffer, R., Ritz, J., Richardson, P.G., Antin, J.H. Biol. Blood Marrow Transplant. (2010) [Pubmed]
  3. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Cutler, C., Antin, J.H. Curr. Opin. Hematol. (2010) [Pubmed]
  4. Patient selection for transplantation in the myelodysplastic syndromes. Cutler, C. Hematol. Oncol. Clin. North Am. (2010) [Pubmed]
  5. Reduced-intensity conditioning and umbilical cord blood transplantation in adults. Cutler, C., Ballen, K. Bone Marrow Transplant. (2009) [Pubmed]
  6. Novel drugs for the prevention and treatment of acute GVHD. Cutler, C., Antin, J.H. Curr. Pharm. Des. (2008) [Pubmed]
  7. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Cutler, C., Stevenson, K., Kim, H.T., Richardson, P., Ho, V.T., Linden, E., Revta, C., Ebert, R., Warren, D., Choi, S., Koreth, J., Armand, P., Alyea, E., Carter, S., Horowitz, M., Antin, J.H., Soiffer, R. Blood (2008) [Pubmed]
  8. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Cutler, C., Li, S., Ho, V.T., Koreth, J., Alyea, E., Soiffer, R.J., Antin, J.H. Blood (2007) [Pubmed]
  9. The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. Cutler, C., Antin, J.H. Curr. Hematol. Malig. Rep (2006) [Pubmed]
  10. Chronic graft-versus-host disease. Cutler, C., Antin, J.H. Curr. Opin. Oncol (2006) [Pubmed]
  11. Rituximab for steroid-refractory chronic graft-versus-host disease. Cutler, C., Miklos, D., Kim, H.T., Treister, N., Woo, S.B., Bienfang, D., Klickstein, L.B., Levin, J., Miller, K., Reynolds, C., Macdonell, R., Pasek, M., Lee, S.J., Ho, V., Soiffer, R., Antin, J.H., Ritz, J., Alyea, E. Blood (2006) [Pubmed]
  12. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Cutler, C., Li, S., Kim, H.T., Laglenne, P., Szeto, K.C., Hoffmeister, L., Harrison, M.J., Ho, V., Alyea, E., Lee, S.J., Soiffer, R., Sonis, S., Antin, J.H. Biol. Blood Marrow Transplant. (2005) [Pubmed]
  13. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Cutler, C., Henry, N.L., Magee, C., Li, S., Kim, H.T., Alyea, E., Ho, V., Lee, S.J., Soiffer, R., Antin, J.H. Biol. Blood Marrow Transplant. (2005) [Pubmed]
  14. An overview of hematopoietic stem cell transplantation. Cutler, C., Antin, J.H. Clin. Chest Med. (2005) [Pubmed]
  15. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Cutler, C., Kim, H.T., Hochberg, E., Ho, V., Alyea, E., Lee, S.J., Fisher, D.C., Miklos, D., Levin, J., Sonis, S., Soiffer, R.J., Antin, J.H. Biol. Blood Marrow Transplant. (2004) [Pubmed]
  16. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Cutler, C., Antin, J.H. Bone Marrow Transplant. (2004) [Pubmed]
  17. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. Cutler, C., Giri, S., Jeyapalan, S., Paniagua, D., Viswanathan, A., Antin, J.H. J. Clin. Oncol. (2001) [Pubmed]
 
WikiGenes - Universities